The U.S. Food and Drug Administration (FDA) has authorized Philip Morris International to market 20 varieties of Zyn nicotine pouches with a modified risk claim, allowing the company to state that switching completely from cigarettes to Zyn can reduce the risk of serious smoking-related diseases. The decision applies specifically to adult smokers who fully replace cigarettes with the nicotine pouches and does not mean the products are safe or risk-free.

FDA officials said the authorization followed an extensive scientific review showing that Zyn users are exposed to fewer harmful chemicals than cigarette smokers. The approved marketing claim covers reduced risks of conditions including lung cancer, heart disease, stroke, emphysema, chronic bronchitis, and mouth cancer. However, the agency stressed that nicotine remains addictive and the products are intended only for adults who already use tobacco.

Public health experts remain divided over the decision. Supporters say providing accurate information about lower-risk alternatives could encourage more smokers to quit combustible cigarettes, while critics worry that the marketing claims could attract young people or non-smokers to nicotine products. The FDA emphasized that the authorization is based on the overall benefit to public health and will continue to monitor the products’ impact on consumers.